Novo Nordisk (NVO)

• Market cap: $452B
• 1 day: -3.40%
• 5 days: -7.23%
• 1 month: -13.64%
• 3 months: -26.04%
• 6 months: -24.45%
• Year to date: -0.36%
• 1 year: 5.51%
• 5 years: 255.24%
• 10 years: 366.70%

About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 72,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

8% more repeat investments, than reductions

Existing positions increased: 674 | Existing positions reduced: 626

0.5% less ownership

Funds ownership: 10.31% [Q2] → 9.81% (-0.5%) [Q3]

7% less funds holding

Funds holding: 1,830 [Q2] → 1,710 (-120) [Q3]

21% less capital invested

Capital invested by funds: $49.8B [Q2] → $39.3B (-$10.5B) [Q3]

32% less call options, than puts

Call options by funds: $791M | Put options by funds: $1.16B

36% less funds holding in top 10

Funds holding in top 10: 87 [Q2] → 56 (-31) [Q3]

45% less first-time investments, than exits

New positions opened: 144 | Existing positions closed: 264

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $156 53% upside
• Avg. target: $159 57% upside
• High target: $160 57% upside

7 analyst ratings

• positive: 7 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Louise Chen 35% 1-year accuracy 56 / 161 met price target	57% upside $160	Overweight Reiterated	6 Nov 2024
BMO Capital Evan David Seigerman 18% 1-year accuracy 3 / 17 met price target	53% upside $156	Outperform Maintained	17 Oct 2024
Cantor Fitzgerald Louise Chen 35% 1-year accuracy 56 / 161 met price target	57% upside $160	Overweight Reiterated	10 Oct 2024
Cantor Fitzgerald Louise Chen 35% 1-year accuracy 56 / 161 met price target	57% upside $160	Overweight Reiterated	20 Sept 2024
Cantor Fitzgerald Louise Chen 35% 1-year accuracy 56 / 161 met price target	57% upside $160	Overweight Reiterated	16 Sept 2024